Evidence map›Paper›PMID 40897230›Full record

ArticleProgress in neuro-psychopharmacology & biological psychiatry2025

Sex-specific dysregulation of the CX

Oscar Porras-Perales, Laura Sánchez-Marín, Dina Medina-Vera, María Flores-López, Laura Martín-Chaves, Milena Boccalon, Nerea Requena-Ocaña, Nuria García-Marchena, Raquel Reviriego, Luis J Santín and 5 more

Abstract read
In one paragraph

Article in Progress in neuro-psychopharmacology & biological psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. The neuroimmune-glutamate hypothesis of addiction.Neuroscience and biobehavioral reviews · 2026
    Review
  2. Cortisol-CXFrontiers in immunology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Oscar Porras-PeralesInstituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Málaga, Spain; Área del Corazón, Hospital Universitario Virgen de la Victoria, Málaga, Spain; Facultad de Psicología, Universidad de Málaga, Málaga, Spain.
Laura Sánchez-MarínInstituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Málaga, Spain; UGC Salud Mental, Hospital Regional Universitario de Málaga, Málaga, Spain.
Dina Medina-VeraInstituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Málaga, Spain; Área del Corazón, Hospital Universitario Virgen de la Victoria, Málaga, Spain; Facultad de Medicina, Universidad de Málaga, Málaga, Spain.
María Flores-LópezInstituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Málaga, Spain; Facultad de Psicología, Universidad de Málaga, Málaga, Spain; UGC Salud Mental, Hospital Regional Universitario de Málaga, Málaga, Spain.
Laura Martín-ChavesInstituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Málaga, Spain; Área del Corazón, Hospital Universitario Virgen de la Victoria, Málaga, Spain; Facultad de Medicina, Universidad de Málaga, Málaga, Spain; CIBER de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain.
Milena BoccalonInstituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Málaga, Spain; UGC Salud Mental, Hospital Regional Universitario de Málaga, Málaga, Spain.
Nerea Requena-OcañaInstituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Málaga, Spain; Facultad de Psicología, Universidad de Málaga, Málaga, Spain.
Nuria García-MarchenaFacultad de Psicología, Universidad Complutense de Madrid, Madrid, Spain.
Raquel ReviriegoInstituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Málaga, Spain; UGC Salud Mental, Hospital Regional Universitario de Málaga, Málaga, Spain.
Luis J SantínInstituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Málaga, Spain; Facultad de Psicología, Universidad de Málaga, Málaga, Spain.
Remi Martin-FardonDepartment of Translational Medicine, Scripps Research, La Jolla, CA, USA.
Manuel Jiménez-NavarroInstituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Málaga, Spain; Área del Corazón, Hospital Universitario Virgen de la Victoria, Málaga, Spain; Facultad de Medicina, Universidad de Málaga, Málaga, Spain; CIBER de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain.
Fernando Rodríguez de FonsecaInstituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Málaga, Spain; Unidad Clínica de Neurología, Hospital Regional Universitario de Málaga, Málaga, Spain.
Antonia SerranoInstituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Málaga, Spain; UGC Salud Mental, Hospital Regional Universitario de Málaga, Málaga, Spain; Department of Translational Medicine, Scripps Research, La Jolla, CA, USA. Electronic address: antonia.serrano@ibima.eu.
Francisco Javier Pavón-MorónInstituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Málaga, Spain; Área del Corazón, Hospital Universitario Virgen de la Victoria, Málaga, Spain; CIBER de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain; Department of Translational Medicine, Scripps Research, La Jolla, CA, USA. Electronic address: javier.pavon@ibima.eu.

Funding

Cocaine-motivated behaviors: development of novel viral-based strategies to target orexinergic input to the infralimbic cortex.R21DA053443 · NIDA · SCRIPPS RESEARCH INSTITUTE, THE · PI MARTIN-FARDON, REMI · 2022 to 2023
$501k
NIDA NIH HHS R21 DA053443
6 · The paper itself

Abstract

Cocaine disrupts neurotransmitter systems and promotes neuroinflammation by activating microglia and altering cytokine signaling. The CX

Indexed as

Chemokine CX3CL1CocaineCocaine-Related DisordersCX3C Chemokine Receptor 1Sex CharacteristicsAdultAmygdalaAnimalsBiomarkersFemaleHippocampusHumansMaleMiddle AgedRatsRats, WistarBiomarkersChemokine CX3CL1CocaineCX3C Chemokine Receptor 1Cx3cl1 protein, ratCX3CR1 protein, humanCX3CR1 protein, ratAbstinenceBiomarkerCocaineFractalkineSexual dimorphismTranslational

Identifiers

PMID40897230
PMCPMC12862095

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.